Genovis’ nanoparticle project published in prestigious Journal of Nuclear Medicine

Genovis’ nanoparticle project published in prestigious Journal of Nuclear
Medicine

The first scientific article from the Sentinel Node project was published in the
Journal of Nuclear Medicine, a highly ranked journal in its field and a forum
for the exchange of clinical and scientific information for nuclear medicine
practitioners.

“The Sentinel Node project is a long-term project and it is wonderful to see the
first results now published, which is proof of its scientific merit and
newsworthiness. We appreciate the interdisciplinary partnership with Lund
BioImaging Center and the Department of Medical Radiation Physics. It provides
us with an opportunity to test our nanostructures in a project backed by
extremely concrete clinical support together with highly qualified,
internationally recognized researchers. Publication also improves the visibility
of our technology in the market. Earlier in January one of our customers
published a stem cell study in which Genovis’ nanostructures make it possible to
follow the stem cells with medical imaging. The momentum provided by references
like these make it exciting to work with business development for the nano
portfolio,” says Sarah Fredriksson, CEO of Genovis AB.

The Journal of Nuclear
Medicine (http://jnm.snmjournals.org/content/early/2012/02/09/jnumed.111.092437.
abstract)

The Sentinel Node project is interdisciplinary and the goal for Genovis is to
produce a multimodal particle that will be used to diagnose (using medical
imaging) extremely small tumors that may quickly spread to nodes, as seen in
breast cancer and melanoma. Tumor cells are spread via the lymphatic system
according to a certain pattern. The first lymph node to receive this drainage is
the “gatekeeper” or “sentinel” node — which is also the name of the development
project that Genovis is conducting in collaboration with the Department of
Medical Radiation Physics at Lund University. During the period the project
focused on how much sentinel node imaging can be improved by optimizing the
design of the nanostructures. The final goal of the project is to produce a
contrast agent that can be used both for diagnostics and as an aid during
surgery. The project is financed by the Swedish Research Council and LMK
Industri AB.

For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel:
+4646 -101235 sarah.fredriksson@genovis.com